Chartered Trade Mark Attorney, Alexandra Nott explores some of the reasons that trade mark protection remains crucial in today’s business environment.
READ MORE
In this insight, Biotechnology partner Kit Wilkins reviews the US Supreme Court’s decision to Consider “Skinny Labels” in Generic Drug Patent Dispute. The decision could result in significant implications of generic medicines in the US.
READ MORE
In this insight, Holly Rocliffe from Dehns Biotechnology group explores the recently handed down decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161[1], in which the Full Court of the Federal Court of Australia (Full Court) has ruled that patent term extension (PTE) is only available for patents which claim an active pharmaceutical ingredient (API).
READ MORE
The first decision from the UPC on sufficiency — handed down in the Amgen v. Sanofi case — provides the first clear guidance on how the court will address whether a patent’s disclosure is sufficient.
READ MORE
In this insight, Dehns Partner Rob Jackson and Conor Wilman from our Technology, Software and Engineering group explore the UPC’s Court of Appeal recent issues of two important decisions about how it will assess inventive step in patent cases.
READ MORE
The intersection between plant sciences and intellectual property (IP) rights (patents and plant variety rights) has been a thorny area for a number of years, particularly in Europe with respect to genetically-modified (GM) plants. In this insight, Biotechnology Partner, Kit Wilkins explores this area and the recent issue of a position paper from AIPPI.
Nera Innovations Ltd. (Nera), a patent holding company owned by Atlantic IP (a non-practising entity), has lost an infringement action against Xiaomi Communications Co., Ltd.; Xiaomi Inc.; Xiaomi Technology Netherlands B. V. and Xiaomi Technology Germany GmBH (Xiaomi).
This decision concerned an application for provisional measures, in particular an anti-anti-suit injunction (‘AASI’), by Avago Technologies International Sales Pte. Limited against the defendant Realtek Semiconductor Corporation
10x Genomics Inc. (10x Genomics) brought an infringement action against Curio Bioscience Inc. (Curio) accusing Curio of indirectly infringing claim 1, and directly infringing claim 14 of 10x’s patent EP 2 697 391 (‘the patent’) in their ‘Curio Seeker Spatial Mapping’ kits, sold in Germany, France and Sweden.
With the Supreme Court set to hear the appeal in Emotional Perception AI’s patent application next week, the UK patent profession eagerly awaits the outcome of the appeal.
Following last week’s historic third consecutive Ferrari outright win at the 24 hours of Le Mans, Dehns Technology, Software and Engineering Associate, Thomas Jeal reflects on another exciting event from this year’s race week: Toyota’s unveiling of their hydrogen combustion engine Hypercar Prototype, the GR LH2 Racing Concept.
Dehns Partner, Tim Wilson explores the recent news on the use of the semicolon plummeting and whether this change impacts the patent drafting of an invention.
More than ever, companies are appreciating the value of trade secrets as key IP assets that can exploited to improve their commercial edge. Trade secret protection varies in different parts of the world but many governments are proactively updating their legal provisions to ensure that innovators are protected.
Panasonic Holdings Corporation (Panasonic) brought an infringement action against Guangdong OPPO Mobile Telecommunications Corp Ltd and OROPE Germany GmBH (OPPO), accusing OPPO of infringing Panasonic’s patent EP 2 568 724 in their 4G-capable products including smartphones and smartwatches. Emily Dekker, Trainee Patent Attorney discusses this matter in more detail.
Huawei brought an action in the Munich local division against Netgear for infringement of EP3611989 in relation to various of its WiFi access point products. Huawei had declared EP’989 to be essential to the IEEE 802.11ax (“WiFi 6”) standard and so was obliged to offer a licence on Fair, Reasonable and Non-Discriminatory (FRAND) terms. However, no licence could be agreed.
Subscribe here for updates on IP news, events and webinars.
|